EBOV-IN-5
EBOV-IN-5 (compound 14) is an antiviral agent that inhibits Ebola virus (EBOV) infection. EBOV-IN-5 inhibits the binding of the EBOV glycoprotein EBOV-GPcl to NPC1, an indispensable host receptor required for viral fusion/entry.
For research use only. We do not sell to patients.
- CAS No.: 68207-15-8
- Formula: C18H21ClN4O3S
- Molecular Weight:408.90
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
Ebola virus[1]
In Vitro
EBOV-IN-5 (compound 14) has a CC50 of 30 μM on HeLa cells and low cytotoxicity on Vero cells with a CC50 >100 μM[1].
EBOV-IN-5 (50 μM) significantly interferes with EBOV - GPcl/NPC1 interaction, IC50 against EBOV-GP-pseudotyped virus (pEBOV) is 4.69 μM[1].
EBOV-IN-5 IC50 against African swine fever virus ASFV is 35.17 μM[1].br /
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 68207-15-8
-
Molecular Weight 408.90
-
Formula C18H21ClN4O3S
-
SMILES
O=C(CN(CC)CC)NNC1=C(SC2=CC(Cl)=CC=C2[N+]([O-])=O)C=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EBOV-IN-5 Related Classifications
HY-160880 Related Classifications
Powered by Bioz